LPA2 antagonist 1

Cat. No.:	HY-18075
CAS No.:	1017606-66-4
Molecular Formula:	$C_{20}H_{23}Cl_2N_5O_2S_2$
Molecular Weight:	500.46
Target:	LPL Receptor
Pathway:	GPCR/G Protein
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (199.82 mM)
DMF : ≥ 100 mg/mL (199.82 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.9982 mL	9.9908 mL	19.9816 mL
5 mM	0.3996 mL	1.9982 mL	3.9963 mL
10 mM	0.1998 mL	0.9991 mL	1.9982 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

LPA2 antagonist 1 is a LPA2 antagonist with an IC_{50} of 17 nM.

IC_{50} & Target

IC50: 17 nM (LPA2)[1]

In Vitro

LPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused by LPA in a doses dependent manner[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Mol Life Sci. 2020 May 28.
- Vet Microbiol. 2021, 109177.
- Research Square Preprint. 2021 Aug.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Beck HP, et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA